Clinical trial

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With…

NCT00096148 · National Cancer Institute (NCI), NIH · Terminated

Key facts

NCT number NCT00096148
Title Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Official title Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia
Lead sponsor National Cancer Institute (NCI), NIH
Status Terminated
Phase Phase 2
Study type Interventional
Conditions Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myelomonocytic Leukemia (M4) and 14 more
Intervention type Biological, Drug, Other
Interventions idarubicin, cytarabine, bevacizumab, laboratory biomarker analysis
Enrollment 120
Start date Oct 1, 2004
Primary completion Nov 1, 2006
First posted Nov 9, 2004
Last update posted Jan 24, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies